Cannabinoids for the Treatment of Schizophrenia: An Overview

Title:Cannabinoids for the Treatment of Schizophrenia: An Overview

Volume: 16 Issue: 17

Author(s): Anna Capasso, Eduardo Sobarzo-Sánchez, Seyed Fazel Nabavi and Luca Rastrelli

Affiliation:

Keywords: Antipsychotics, Cannabis sativa, Cannabinoids, Cannabidiol, THC, Natural products, Schizophrenia.

Abstract: Cannabinoids are found to be very useful in psychiatry because of their antipsychotic properties suggesting a therapeutic use as neuroleptic agents in limiting psychotic diseases. Cannabinoids treatments are both able to reduce the typical symptoms of schizophrenia and to slow down the disease aggravation. In the present review, we reported recent studies supporting the idea that the cannabinoid system may modulate the activity of the striatum and temporal cortex linked to psychosis and schizophrenia. Furthermore, anatomical, electrophysiological, pharmacological and biochemical data suggest that the psychotic disorders related to the impaired cannabinoid system may lead to the development of novel compounds that selectively target specific elements of the cannabinoid system.

Cite this article as:

Capasso Anna, Sobarzo-Sánchez Eduardo, Fazel Nabavi Seyed and Rastrelli Luca, Cannabinoids for the Treatment of Schizophrenia: An Overview, Current Topics in Medicinal Chemistry 2016; 16(17) . https://dx.doi.org/10.2174/1568026616666160204122033